(+)-(R)-2-(benzyloxy)butanal | 80928-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-(R)-2-(benzyloxy)butanal
• 英文别名: (R)-(+)-2-Benzyloxybutyraldehyde；(r)-2-Benzyloxybutanal；(2R)-2-phenylmethoxybutanal
• CAS: 80928-05-8
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: YTXIEUATJGWTOC-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+)-(R)-2-(benzyloxy)butanal 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-2-benzyloxy-1-butanol
  参考文献：
  名称：

  Alkylation and aldol reactions of acyl derivatives of N-1-(1′-naphthyl)ethyl-O-tert-butylhydroxylamine: asymmetric synthesis of α-alkoxy-, α-substituted-β-alkoxy- and α,β-dialkoxyaldehydes

  摘要：

  Treatment of a range of O-protected glycolate derivatives of the chiral auxiliary N-1-(1'-naphthyl)ethyl-O-tert-butylhydroxylamine with KHMDS in the presence of 18-crown-6 followed by addition of an alkyl halide generates alpha-substituted derivatives with very high levels of diastereoselectivity. Alternatively, reaction of the potassium enolate of a propanoate or O-protected glycolate derivative of N-1-(1'-naphthyl)ethyl-O-tert-butylhydroxylamine with a range of aldehydes gives syn-aldol products with high levels of diastereoselectivity. These adducts may be reductively cleaved with LiAlH(4) to give enantiopure alpha-alkoxy-, alpha-substituted-beta-alkoxy- and alpha,beta-dialkoxyaldehydes in good yield. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.03.105
• 作为产物：
  描述：

  (2S,3S,4R)-4-Benzyloxy-hexane-2,3-diol 在 过碘酸 作用下， 以 四氢呋喃 为溶剂， 生成 (+)-(R)-2-(benzyloxy)butanal
  参考文献：
  名称：

  在格氏试剂向α，β-二烷氧基和手性醛加成的空间过程中。（+）和（-）-和-brevicomin的合成

  摘要：

  BrMgCH的另外2 CH 3到与醛（1）和（2）的形式（3）+（6）和（9）+（10）6进行：4和8：2 -分别选择性。由（3）和（6）制备（2 ）和（2 ）-2-苄氧基丁醛（13）和（14）。的上（13）和（14）具有6个前进此外：4，-选择性，以制备气体色谱分离后，得到的对映体形式的-和- brevicomin（19），（21）和（20），（22） 。

  DOI：

  10.1016/s0040-4039(01)82054-2

文献信息

• Bel-Rhlid, Rachid; Renard, Michel F.; Veschambre, Henri, Bulletin de la Societe Chimique de France, 1996, vol. 133, # 10, p. 1011 - 1021
  作者：Bel-Rhlid, Rachid、Renard, Michel F.、Veschambre, Henri

  DOI：——

  日期：——
• Enders, Dieter; Reinhold, Ulrich, Liebigs Annalen, 1996, # 1, p. 11 - 26
  作者：Enders, Dieter、Reinhold, Ulrich

  DOI：——

  日期：——
• Asymmetric synthesis of the optically active piperidine alkaloid (+)-β-conhydrine
  作者：Stéphane Lebrun、Axel Couture、Eric Deniau、Pierre Grandclaudon

  DOI：10.1016/j.tetasy.2008.04.021

  日期：2008.5

  A new approach for the stereoselective synthesis of the piperidine alkaloid (+)-beta-conhydrine based upon a highly diastereoselective 1,2-nucleophilic addition reaction onto a diastereopure hydrazone and ring-closing metathesis as the key steps has been developed. (C) 2008 Elsevier Ltd. All rights reserved.
• Steric and Electronic Effects in Conformational Preferences of C1-Oxygenated Chiral Alkenes
  作者：Benjamin W. Gung、Jason P. Melnick、Mark A. Wolf、Amanda King

  DOI：10.1021/jo00112a012

  日期：1995.4

  A variable temperature NMR study shows that the benzyl protective group on the hydroxy function of a chiral allylic alcohol enhances the CH eclipsed form (I). On the other hand, various silyl ethers enhance the preference for the CO eclipsed conformer. However, when both the allylic R group and the hydroxy protective group are bulky (R tert-butyl, P = TIPS), the staggered conformation of the chiral alkene becomes preferred. An acetate group does not have an apparent effect on the conformational preference of the protected allylic alcohol. These facts are explained in terms of steric and electronic interactions.
• SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
  申请人：Japan Tobacco Inc.

  公开号：US20160046641A1

  公开（公告）日：2016-02-18

  [Problem] Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. [Solving Means] The present invention relates to a compound represented by the following formula [I] or [II] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.